, Singapore
196 views
Photo from MAS

MAS fines doctor $120,000 for insider trading

The case involved purchases of Singapore Medical Group shares before its privatisation offer was announced.

The Monetary Authority of Singapore has imposed a $120,000 civil penalty on Dr Chua Han Boon Kenneth for insider trading in shares of Singapore Medical Group Limited.

Before the company announced a voluntary conditional general offer from TLW Success to privatise it, Chua was informed of the plan and asked to sign an irrevocable undertaking supporting the offer.

Whilst possessing the non-public, materially price-sensitive information, he bought 210,000 Singapore Medical Group shares on 6 and 7 September 2022 for a total of $67,200.

Chua admitted breaching Section 218(2)(a) of the Securities and Futures Act and paid the penalty without court proceedings.

He also gave a voluntary undertaking not to serve as a company director or participate in company management for two years.

The enforcement action followed a joint investigation by MAS and the Commercial Affairs Department after a referral from Singapore Exchange Regulation.

MAS said the action was taken under the civil penalty regime and did not involve criminal sanctions.

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.